CAPRICOR THERAPEUTICS Reports Second-Quarter Earnings for FY2023
August 13, 2023
🌥️Earnings Overview
CAPRICOR THERAPEUTICS ($NASDAQ:CAPR) announced its earnings results for the second quarter of FY2023 on June 30 2023. Total revenue for the quarter was USD 3.9 million, a significant rise from the 0.0 million reported in the same quarter of the previous year. Net income for the quarter stood at USD -7.4 million, a small dip from the -7.1 million reported the year before.
Share Price
This marks a strong start for the company’s performance this quarter, as the stock has increased steadily since then. The company has been diligently working to meet FDA standards and get their product approved. The results of the second quarter earnings report has shown that the company is making steady progress in this endeavour. CAPRICOR THERAPEUTICS has also been expanding their research and development capacity by investing in new technologies and personnel. These investments have enabled them to make great strides in the development of their products and treatment options.
Overall, CAPRICOR THERAPEUTICS has reported positive earnings for the second quarter, showing promise for the remainder of the year. The stock performance has been a testament to this progress and could serve as an indicator of an even more successful future for the company. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Capricor Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 9.46 | -29.23 | -322.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Capricor Therapeutics. More…
| Operations | Investing | Financing |
| -14.92 | -35.07 | 4.87 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Capricor Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 46.01 | 43.28 | 0.25 |
Key Ratios Snapshot
Some of the financial key ratios for Capricor Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 150.8% | – | -322.3% |
| FCF Margin | ROE | ROA |
| -191.5% | -306.9% | -41.4% |
Analysis
At GoodWhale, we have analyzed CAPRICOR THERAPEUTICS‘s financials and based on our Star Chart, CAPRICOR THERAPEUTICS is strong in growth, medium in asset, and weak in dividend and profitability. Its intermediate health score is 4/10 which means that it has the capability to pay off debt and fund future operations. The company is classified as a ‘cheetah’, which means that it has achieved high revenue or earnings growth, but is considered less stable due to lower profitability. Investors who are looking for high growth potential with some risk may be interested in CAPRICOR THERAPEUTICS. They should be aware that the company may not be able to maintain its current growth rate due to its lower profitability. Moreover, investors should also consider the risks associated with investing in biopharmaceutical companies, such as regulatory or clinical trial risks. More…
Peers
These companies include Nascent Biotech Inc, Adynxx Inc, and Brickell Biotech Inc. All of these companies are in competition with each other in order to provide the best products and services to their customers.
– Nascent Biotech Inc ($OTCPK:NBIO)
Nascent Biotech Inc is a clinical-stage biopharmaceutical company that focuses on the development of novel therapies for cancer and autoimmune diseases. The company’s market cap is $29.27 million and its ROE is 55.87%. Nascent Biotech is headquartered in San Diego, California.
– Adynxx Inc ($OTCPK:ADYX)
Adynxx Inc is a clinical-stage biopharmaceutical company focused on developing treatments for pain. The company’s lead product candidate, ADYX-002, is a topical gel formulation of the non-opioid analgesic, ibuprofen, in development for the treatment of acute pain. Adynxx is also developing ADYX-003, a topical formulation of the N-methyl-D-aspartate (NMDA) receptor antagonist, ketamine, for the treatment of chronic pain.
Summary
CAPRICOR THERAPEUTICS recently reported its second quarter results for the FY2023, showing total revenue of USD 3.9 million and net income of USD -7.4 million. The total revenue increased significantly from the 0.0 million reported in the same quarter of the previous year, however the net income declined slightly from -7.1 million in Q2 of FY2022. The stock price of the company moved up on the same day as the announcement. Overall, investors should consider CAPRICOR THERAPEUTICS a potential investment opportunity as it appears to have significant potential for growth, and the recent earnings results demonstrate its ability to generate revenue.
However, investors must consider the net income when evaluating potential returns, as the company is currently operating at a loss.
Related Posts
Recent Posts
